Silexion Seeks 175M Share Authorization Increase and Reverse Split to Avoid Nasdaq Delisting
SLXN is trading near its 52-week low of $0.36 (0.0% above the low).
Summary
Silexion Therapeutics is seeking shareholder approval for a 175 million share authorization increase and a reverse split of up to 1-for-15 to maintain Nasdaq listing compliance. The company faces delisting after failing the minimum shareholders' equity requirement and needs the share increase to raise capital.
Key Events · Corporate Governance and Compliance · SLXN
-
175M Share Authorization Increase Proposed
Proposal 1 would increase authorized shares from 15.9 million to 190.9 million — an 1,100% increase — to enable financing and maintain Nasdaq's $2.5 million minimum shareholders' equity requirement.
-
Reverse Split of 1-for-7 to 1-for-15 Proposed
Proposal 2 authorizes the board to effect a reverse split at a ratio between 1-for-7 and 1-for-15 to lift the share price above Nasdaq's $1.00 minimum bid requirement.
-
Nasdaq Delisting Risk
The company received a delisting notice on August 21, 2026 for failing the minimum shareholders' equity requirement. Shareholders' equity was only $44 thousand as of June 30, 2026, adjusted to approximately $3.2 million through August 13.
-
Massive Dilution Potential
The filing shows a negative remaining authorized share balance of -19.8 million shares after accounting for warrants, ATM commitments, and the sponsor note conversion, indicating severe share capital depletion.
Analysis · SLXN · Life Sciences
Silexion Therapeutics is asking shareholders to approve a massive 175 million share authorization increase and a reverse split of up to 1-for-15 at a September 9 meeting. The company is fighting to stay listed on Nasdaq after receiving a delisting notice on August 21 for failing the minimum shareholders' equity requirement. With only $44 thousand in shareholders' equity as of June 30 and a stock price of $0.36, the company needs both the share increase to raise capital and the reverse split to lift the price above $1.00. The authorization increase would expand authorized shares from 15.9 million to 190.9 million — an 1,100% increase — giving the board enormous flexibility to issue shares for financing, warrant conversions, and the ATM program. This is a survival move for a company with going concern doubts and a sponsor lawsuit over a $3.4 million note.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.36 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.